Liquidia stock faces patent risk after two claims are found valid

Liquidia Corporation stock was last at USD 26.68 on Nasdaq on October 7, 2026, up 2.97 percent, as a court dispute over YUTREPIA remained central to the investment case. According to Trivano on October 5, 2026, a federal court found two of six asserted United Therapeutics patent claims valid and infringed in connection with YUTREPIA.

Patent ruling raises commercial stakes

The ruling created a direct risk for Liquidia's lead product, an inhaled treprostinil treatment for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company plans to remove the PH-ILD indication from the product label, while United Therapeutics has sought an injunction, according to Trivano.

The same October 5 release said Levi and Korsinsky was investigating whether Liquidia statements about the patent litigation and its outlook for more than USD 1 billion in 2027 net revenue were potentially misleading. The notice itself does not establish wrongdoing, but it adds a legal overhang to a commercial forecast that depends heavily on YUTREPIA.

Q2 revenue surged, EPS missed

Liquidia's Q2 2026 revenue reached USD 171.68 million, a 1,842.1 percent increase from the year-earlier quarter, while diluted EPS was USD 0.74. According to MarketBeat, EPS missed the USD 0.76 consensus estimate by USD 0.02, although revenue exceeded the USD 168.48 million estimate.

MarketBeat reported on September 28, 2026, that 11 analysts carried a Hold consensus for Liquidia, with five Buy ratings, one Strong Buy, three Hold ratings and two Sell ratings. The average 12-month price target was USD 98.08, putting the target 267.6 percent above the October 7 price.

Stock remains below yearly high

The Nasdaq quote stood 71.5 percent below the 52-week high of USD 93.61 and 21.6 percent above the low of USD 21.94 on October 7, 2026. Trading volume reached 6,961,204 shares, while the market capitalization was USD 2.4 billion.

For investors, the central calculation is whether YUTREPIA's commercial expansion can continue after the patent ruling. The Q2 revenue increase supplies operating momentum, while the label change and litigation risk put the more than USD 1 billion 2027 revenue outlook under pressure.

More news and analyses on Liquidia stock